Disis Mary L
Division of Oncology, University of Washington, Seattle, WA 98195-6527, USA.
Breast Dis. 2002;15:83-90. doi: 10.3233/bd-2002-15109.
Breast cancer is an immunogenic tumor. Over the last decade, investigations have shown that patients with breast cancer have pre-existent immune responses, both humoral and cellular, against a variety of proteins expressed in their tumors. Researchers using genomic and proteomic techniques have defined dozens of proteins that may serve as immunologic targets in breast cancer patients. In addition, other investigators focusing on a more directed approach of evaluating well-defined breast cancer proteins that are immunogenic have begun to translate some of the candidate antigens into human clinical trials of immune-based therapies in breast cancer. Immunogenic proteins associated with breast cancer are abundant. The major experimental question now facing breast cancer immunologists is how to prioritize these many candidate antigens for further evaluation for clinical use.
乳腺癌是一种免疫原性肿瘤。在过去十年中,研究表明乳腺癌患者对其肿瘤中表达的多种蛋白质预先存在体液免疫和细胞免疫反应。使用基因组和蛋白质组技术的研究人员已经确定了数十种可能作为乳腺癌患者免疫靶点的蛋白质。此外,其他专注于更有针对性地评估具有免疫原性的明确乳腺癌蛋白质的研究人员,已开始将一些候选抗原转化为乳腺癌免疫疗法的人体临床试验。与乳腺癌相关的免疫原性蛋白质丰富。乳腺癌免疫学家目前面临的主要实验问题是如何对这些众多候选抗原进行优先级排序,以便进一步评估其临床应用。